| Symbol | XTLB |
|---|---|
| Name | XTL BIOPHARMACEUTICALS LTD |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Pharmaceutical Preparations |
| Address | XTL BIOPHARMACEUTICALS LTD, NEW YORK, NY 10016 |
| Telephone | 972 9 955 7080 |
| Fax | 09-9519708 |
| ir@xtlbio.com | |
| Website | https://www.xtlbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ;TASE |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001023549 |
| Description | XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Additional info from NASDAQ: |
NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient and Delinquent. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient and Delinquent. New value: Normal.
Read moreNew Form 20-F - XTL BIOPHARMACEUTICALS LTD <b>Filed:</b> 2026-06-30 <b>AccNo:</b> 0001213900-26-073831 <b>Size:</b> 9 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00597649 | A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associa… | Phase2 | Chronic Peripheral Neuropathy Pain in Diabetics | Terminated | 2007-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00553592 | Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain … | Phase2 | Diabetic Peripheral Neuropathy | Unknown | 2007-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00255359 | Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are … | Phase1 | Chronic Hepatitis C Virus Infection | Withdrawn | 2006-02-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00300807 | Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection | Phase1 | Hepatitis C | Unknown | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Bicifadine | DRUG | Phase PHASE2 | Chronic Peripheral Neuropathy Pain in Diabetics | TERMINATED | NCT00597649 |
| XTL 6865 | DRUG | Phase PHASE1 | Hepatitis C | UNKNOWN | NCT00300807 |
| XTL-2125 | DRUG | Phase PHASE1 | Chronic Hepatitis C Virus Infection | WITHDRAWN | NCT00255359 |